These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 20346244

  • 1. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
    Laskari K, Zintzaras E, Tzioufas AG.
    Clin Exp Rheumatol; 2010; 28(1):83-6. PubMed ID: 20346244
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, Kumar V, Kohli HS, Sakhuja V, Jha V, Gupta KL.
    Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
    [Abstract] [Full Text] [Related]

  • 4. [The risk of sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy].
    Liu G, Chen Y, Wang L, Zuo C, Xie Q, Wang Z, Lin M.
    Hua Xi Yi Ke Da Xue Xue Bao; 2001 Jun; 32(2):294-5, 306. PubMed ID: 12600113
    [Abstract] [Full Text] [Related]

  • 5. Fertility, ovarian failure, and pregnancy outcome in SLE patients treated with intravenous cyclophosphamide in Saudi Arabia.
    Alarfaj AS, Khalil N.
    Clin Rheumatol; 2014 Dec; 33(12):1731-6. PubMed ID: 24894105
    [Abstract] [Full Text] [Related]

  • 6. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus.
    Fassbinder T, Saunders U, Mickholz E, Jung E, Becker H, Schlüter B, Jacobi AM.
    Arthritis Res Ther; 2015 Apr 03; 17(1):92. PubMed ID: 25890338
    [Abstract] [Full Text] [Related]

  • 7. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, Meroni P, Messa P, Sinico AR.
    Rheumatology (Oxford); 2014 Sep 03; 53(9):1570-7. PubMed ID: 24505125
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prevalence of premature ovarian failure in systemic lupus erythematosus patients treated with immunosuppressive agents in Thailand.
    Akawatcharangura P, Taechakraichana N, Osiri M.
    Lupus; 2016 Apr 03; 25(4):436-44. PubMed ID: 26621134
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.
    Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, Teo SM, Wong HS, Tan SY, Shaariah W, Tan CC, Morad Z.
    Nephrology (Carlton); 2005 Oct 03; 10(5):504-10. PubMed ID: 16221103
    [Abstract] [Full Text] [Related]

  • 13. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.
    Koga T, Umeda M, Endo Y, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Murakami N, Kitajima M, Kawakami A.
    Int J Rheum Dis; 2018 Jun 03; 21(6):1287-1292. PubMed ID: 29879312
    [Abstract] [Full Text] [Related]

  • 14. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide.
    Katsifis GE, Tzioufas AG.
    Lupus; 2004 Jun 03; 13(9):673-8. PubMed ID: 15485101
    [Abstract] [Full Text] [Related]

  • 15. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
    Mok CC, Lau CS, Wong RW.
    Arthritis Rheum; 1998 May 03; 41(5):831-7. PubMed ID: 9588734
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Current therapies for lupus nephritis in an ethnically heterogeneous cohort.
    Rivera TL, Belmont HM, Malani S, Latorre M, Benton L, Weisstuch J, Barisoni L, Tseng CE, Izmirly PM, Buyon JP, Askanase AD.
    J Rheumatol; 2009 Feb 03; 36(2):298-305. PubMed ID: 19040310
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC.
    Am J Med; 2006 Apr 03; 119(4):355.e25-33. PubMed ID: 16564783
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.